MedTrace Logo

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00691405 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2012-02-22

No results posted yet for this study

Summary

A dose ranging study to evaluate the safety, tolerability and efficacy of arformoterol (given once or twice a day) in subjects with COPD.

Conditions

Interventions

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 5 mcg BID

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 15 mcg BID

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 25 mcg BID

DRUG

Placebo

Placebo inhalation solution BID

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 15 mcg QD

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 25 mcg QD

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 50 mcg QD

DRUG

Placebo

Placebo inhalation solution QD

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2004-05-31
Completion
2004-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00691405 on ClinicalTrials.gov